Etanercept biosimilar (Intas Biopharmaceuticals)

依那西普生物类似药 (Intas Biopharmaceuticals)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (Intas Biopharmaceuticals)
Drug Alias Name依那西普生物仿制药 (Intas Biopharmaceuticals)Etanercept biosimilar (Intas Pharmaceuticals)Intacept
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidArthritis, Juvenile +[5] 
Global Approved IndicationsPsoriasisArthritis, RheumatoidArthritis, Juvenile +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2015/03/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIntas Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesIntas Biopharmaceuticals
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritis, RheumatoidArthritis, Juvenile +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A